Skip to main content

International Psoriasis Council

International Psoriasis Council
subscribe
6   What's New
Search
subscribe
Search

Advancing Knowledge. Improving Care.

Josep

Riera-Monroig

,

MD

Dermatologist
Hospital Clínic de Barcelona
Barcelona
,
Spain
2024 Fellow
IPC Jr. Councilor
Request an Update
Dr. Josep Riera-Monroig is a consultant dermatologist leading the Psoriasis Unit at the Department of Dermatology, Hospital Clínic de Barcelona, Spain. He is also a lecturer at the Faculty of Medicine, University of Barcelona. His work in psoriasis focuses on novel therapeutic approaches and identifying exposome-related triggers, such as microbiome alterations and the characteristics of emotional stressors linked to disease flares. His clinical expertise also includes rare genetic disorders, such as generalized pustular psoriasis and disorders of epidermal differentiation. Dr. Riera-Monroig has served as principal investigator in multiple clinical trials and research studies. He has participated in educational programs such as the International Alliance for Global Health Dermatology (GLODERM) and serves as Secretary of the Catalan Society of Dermatology and Venereology. He is also an active member of the Spanish Psoriasis Group of the Academia Española de Dermatología y Venereología (AEDV). For his IPC Fellowship, Dr. Riera-Monroig undertook research training with IPC Councilor Dr. Wilson Liao at the University of California, San Francisco.
Last Updated:
01/01/2025

Areas of Interest

Environmental & emotional triggers, Palmoplantar involvement, Palmoplantar pustulosis, Treatment optimization, Biomarkers to predict psoriatic arthritis

Languages Spoken

English, Spanish

Involvement with Other Organization(s)

Dr. Riera-Monroig collaborates with the psoriasis patient association, Acción Psoriasis, and organizations for rare conditions such as DEBRA and ASIC. He also serves on his hospital’s drug approval committee.
Recent publications

Featured

Blog

How Psoriasis Severity Is Defined, And What NPF’s Endorsement of IPC’s Framework Means.

Learn how psoriasis severity is defined and what NPF’s endorsement of IPC’s framework means for classifying mild…

Read More

Blog

Honoring Professor Hervé Bachelez for His Service on the IPC Board.

The International Psoriasis Council recognizes Professor Hervé Bachelez, MD, PhD, for his years of service on the IPC…

Read More

Blog

Shaping the Future of Psoriasis Care: IPC's 2025 International Fellows.

Discover how the 2025 IPC International Fellows navigated a year of global learning, collaboration, and growth to help…

Read More

Video

Case Presentation II: Psoriasis Symptoms.

IPC Junior Councilor Dr. Josep Riera presents a complex case of a patient with sensitive nail changes and pain,…

Watch Video

PDF

A Report from the 34th Annual European Academy of Dermatology and Venereology (EADV) Congress.

Key takeaways from the 2025 EADV Congress in Paris, including the IPC Symposium on psoriasis, Free Communication…

View Report

Blog

A Year of Growth and Collaboration: IPC's 2024 International Fellows.

The 2024 IPC International Fellows reflect on their global dermatological journey, sharing their unique experiences,…

Read More

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026